Antibacterial drug resistance in Latin America: Consequences for infectious disease control;Resistencia a los antibacterianos en América Latina: Consecuencias para la infectología

Revista Panamericana de Salud Publica/Pan American Journal of Public Health

Volumn 30, Issue 6, 2011, Pages 519-528

  Casellas, José María ^a  

^a Asociación Panamericana de Infectología API   (Argentina)

Author keywords

Drug resistance, Bacterial; Drug resistance, Microbial; Enterobacteriaceae; Gram positive bacteria; Latin America

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE;

ANTIBIOTICS; ANTIMICROBIAL ACTIVITY; BACTERIUM; DISEASE CONTROL; DRUG RESISTANCE; ENZYME ACTIVITY; HEALTH RISK; HOSPITAL SECTOR; PUBLIC HEALTH;

ACINETOBACTER; ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; ARTICLE; BIOFILM; CLASSIFICATION; DEVELOPING COUNTRY; DRUG EFFECT; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; ENTEROCOCCUS; ENZYMOLOGY; GENETICS; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; GRAM POSITIVE INFECTION; HEALTH; HUMAN; INFECTION CONTROL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; MULTIDRUG RESISTANCE; PHYSIOLOGY; PSEUDOMONAS INFECTION; SOUTH AND CENTRAL AMERICA; STREPTOCOCCUS;

ACINETOBACTER; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; BIOFILMS; DEVELOPING COUNTRIES; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; ENTEROCOCCUS; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INFECTION CONTROL; LATIN AMERICA; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PSEUDOMONAS INFECTIONS; STREPTOCOCCUS; WORLD HEALTH;

LATIN AMERICA; UNITED STATES;

ACINETOBACTER; BACILLI (CLASS); BACTERIA (MICROORGANISMS); ENTEROBACTERIACEAE; ENTEROCOCCUS; NEGIBACTERIA; POSIBACTERIA; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 84859961545     PISSN: 10204989     EISSN: 16805348     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Casellas JM, Quinteros MG. A Latin American "point de vue". In: Epidemiology, control, and treatment options of infections caused by extended-spectrum beta-lactamase producers. Amábile-Cuevas CF, ed. Antimicrobial resistance in bacteria. Norfolk, UK: Horizon Bioscience; 2007. P. 99-122.
2. Casellas JM. Resistencia bacteriana. Implicancias infectológicas. En: Cecchini E, González Ayala SE, eds. Infectología y enfermedades infecciosas. Buenos Aires: Ediciones Journal; 2008. P. 1135-44.
3. Edmon MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three year analysis. Clin Infect Dis. 1999;29(2):239-44. (Pubitemid 29380177)
4. Asociación Argentina de Microbiología. Informe SIR 2005. Bol Asoc Arg Microbiol. 2005; 172.
5. a encuesta del Comité de Resistencia a Antimicrobianos de la Asociación Panamericana de Infectología. Rev Panam Infectol. 2006;8(3):48-5.
6. Neu HC. The crisis in antibiotic resistance. Science. 1992;257(5073):1064-73.
7. Rice LB. Antimicrobial resistance in Grampositive bacteria. Am J. Med. 2006;34(5) (1 Suppl):S11-S9.
8. Sola C, Cortes P, Saka HA, Córdoba MRSA Collaborative Study Group, Vindel A, Bocco JL. Evolution and molecular characterization of methicillin resistant Staphylococcus aureus epidemic and sporadic clones in Córdoba, Argentina. J Clin Microbiol. 2006;44(1):192-200. (Pubitemid 43100600)
9. Saravolatz LD, Pohlod DJ, Arking LM. Community-acquired methicillin-resistant Staphylococcus aureus infections: a new source for nosocomial outbreaks. Ann Intern Med. 1982;97(3):325-9. (Pubitemid 12061578)
10. Zetola N, Francis JS, Nuermberger EL, Bishai WR. Community-acquired methicillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis. 2005;5(5):275-86. (Pubitemid 40602247)
11. Lina G, Piémont Y, Godail-Gamot F, Bes M, Peter MO, Gauduchon V, et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis. 1999; 29(5):1128-32. (Pubitemid 30265628)
12. Mongkolrattanothai K, Boyle S, Kahana MD, Daum RS. Severe Staphylococcus aureus infections caused by clonally related communityacquired methicillin-susceptible and methicillin-resistant isolates. Clin Infect Dis. 2003;37(8):1050-8. (Pubitemid 37323659)
13. Jacoby GA. Mechanisms of resistance to quinolones. Clin Infect Dis. 2005;41(Suppl 2): S120-S6. (Pubitemid 40962482)
14. Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: A general strategy derived from fluoroquinolones studies. Clin Infect Dis. 2001;33(Suppl 3):S147-S56. (Pubitemid 32835784)
15. Casellas JM , Cha Torea JC. Guía de terapéutica antimicrobiana. En: Terapia Intensiva. Wyeth-Ayerst Arg. ed. Buenos Aires, Argentina: 2000.
16. Roberts SM, Freeman AF, Harrington SM, Holland SM, Murray PR, Zelazny AM. Linezolid-resistant Staphylococcus aureus in two pediatric patients receiving low-dose linezolid therapy. Pediatric Infect Dis J. 2006; 25(6):562-4. (Pubitemid 43863372)
17. Fritsche TR, Rennie RP, Goldstein BP, Jones RN. Comparison of dalbavancin MIC values determined by Etest (AB BIODISK) and reference dilution methods using Gram-positive organisms. J Clin Microbiol. 2006;44(8):2988-90. (Pubitemid 44228601)
18. Mangili A, Bica I, Snydman DR, Hamer DH. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2005;40(7):1058-60. (Pubitemid 40418318)
19. Denis O, Deplano A, Nonhoff C, Hallin M, De Ryck R, Vanhoof R, et al. In vitro activity of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillinresistant Staphylococcus aureus strains from a national survey of Belgian hospitals. Antimicrob Agents Chemother. 2006;50(8): 2680-5. (Pubitemid 44198687)
20. Tomasz A. The pneumococcus at the gates. N Engl J Med. 1995;333(8):514-5.
21. Pallares R, Liñares J, Vadillo M, Cabellos C, Manresa F, Viladrich PF, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med. 1995;333(8): 474-80.
22. Hortal M, Ruvinsky R, Rossi A, Agudelo CI, Castañeda E, Brandileone C, et al. Impact of Streptococcus pneumoniae on pneumonia in Latin American children. SIREVA-Vigía Group. Rev Panam Salud Publica. 2000;8(3):185-95.
23. Jones ME, Draghi DC, Thornsberry C, Karlowsky JA, Sahm DF, Wenzel RP. Emerging resistance among bacterial pathogens in the intensive care unit-a European and North American Surveillance study (2000-2002). Ann Clin Microbiol Antimicrob. 2004; 3:14.
24. Rossi A, Ruvinsky R, Regueira M, Corso A, Pace J, Gentile A, et al. Distribution of capsular types and penicillin-resistance of strains of Streptococcus pneumoniae causing systemic infections in Argentinian children under 5 years of age. Streptococcus pneumoniae Working Group. Microb Drug Resistance. 1997;3(2): 135-40. (Pubitemid 27250963)
25. Faccone D, Andres P, Galas M, Tokumoto M, Rosato A, Corso A. Emergence of a Streptococcus pneumoniae clinical isolate highly resistant to telithromycin and fluoroquinolones. J Clin Microbiol. 2005;43(11):5800-3. (Pubitemid 41612369)
26. Martone WJ. Spread of vancomycin-resistant enterococci: why did it happen in the United States? Infect Control Hosp Epidemiol. 1998; 19(8):539-45. (Pubitemid 128472676)
27. Arthur M, Reynolds P, Courvalin P. Glycopeptide resistance in enterococci. Trends Microbiol. 1996;4(10):401-7. (Pubitemid 26325131)
28. Donskey CJ, Hanrahan JA, Hutton RA, Rice LB. Effect of parenteral antibiotic administration on persistence of vancomycin-resistant Enterococcus faecium in the mouse gastrointestinal tract. J Infect Dis. 1999;180(2):384-90. (Pubitemid 30256319)
29. Livermore D. Beta-lactamases in laboratory and clinical resistance. Clin Microbiol Rev. 1995;8(4):557-84.
30. Datta N, Kontomichalou P. Penicillase synthesis controlled by infectious R factors in Enterobacteriaceae. Nature. 1965;208:239-41.
31. Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection. 1983;11(6): 315-7. (Pubitemid 14213754)
32. Bauernfeind A, Casellas JM, Goldberg M, Holley M, Jungwirth R, Mangold P, et al. A new plasmidic cefotaximase from patients infected with Salmonella typhimurium. Infection. 1992;20(3):158-63.
33. Casellas JM, Tomé G, Bantar C, Bertolini P, Blázquez N, Borda N, et al. Argentinean collaborative multicenter study on the in vitro comparative activity of piperacillintazobactam against selected bacterial isolates recovered from hospitalized patients. Diagn Microbiol Infect Dis. 2003;47(3):527-37. (Pubitemid 37338518)
34. Casellas JM, Goldberg M. Incidence of strains producing extended spectrum beta-lactamases in Argentina. Infection. 1989;17(6):434-6. (Pubitemid 20013480)
35. Paterson DL, Ko WC, Von Gottberg A, Casellas JM, Mulazimoglu L, Klugman KP, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrumb-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol. 2001; 39(6):2206-12. (Pubitemid 32531482)
36. Paterson DL, Mulazimoglu L, Casellas JM, Ko WC, Goossens H, von Gottberg A, et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum-b-lactamase production in Klebsiellla pneumoniae isolates causing bacteremia. Clin Infect Dis. 2000;30(3):473-8. (Pubitemid 30205291)
37. Craig WA, Bhavnani SM, Ambrose PG. The inoculum effect: fact or artifact? Diagn Microbiol Infect Dis. 2004;50(4):229-30. (Pubitemid 39593144)
38. Paterson DL. Resistance in Gram-negative bacteria: enterobacteriaceae. Am J Med. 2006; 119(6 supl 1):S20-S8.
39. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18(4):657-86.
40. Martínez-Martínez L, Hernández-Allés S, Albertí S, Tomás JM, Benedi VJ, Jacoby GA. In vivo selections of porin-deficient mutants of Klebsiella pneumoniae with increased resistance to cefoxitin and expanded-spectrum-cephalosporins. Antimicrob Agents Chemoter. 1996;40(2):342-8. (Pubitemid 26049344)
41. Lincopan N, McCulloch JA, Reinert C, Cassettari VC, Gales AC, Mamizuka EM. First isolation of metallo-b-lactamase-producing multiresistant Klebsiella pneumoniae from a patient in Brazil. J Clin Microbiol. 2005;43(1): 516-9. (Pubitemid 40096362)
42. Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, et al. Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother. 2001;45(4): 1151-61. (Pubitemid 32230996)
43. Villegas MV, Lolans K, Correa A, Suárez CJ, López JH, Vallejo M, et al. First detection of the plasmid-mediated Class A carbapenemase KPC-2 in clinical isolates of Klebsiella pneumoniae from South America. Antimicrob Agents Chemother. 2006;50(8):2880-2. (Pubitemid 44198721)
44. Casellas JM, Borda N, Tomé G, Farinati A, Notario R, Cocconi E, et al. Fosfomicina sódica y cálcica, alternativa para tratamiento de enterobacterias y Pseudomonas aeruginosa productoras de BLEE o carbapenemasas y estafilococos resistentes. XI Congreso Panamericano de Infectología. Punta del Este, Uruguay 2011. Abst SO6-35. P. 75.
45. Casellas JM, Lovesio C, Notario R. Colistina. Volver a vivir en el siglo XXI. Res Quimioter Antimicrob Latinoamericana. 2004;2(6)Supl 1: S1-S8.
46. Martínez-Martínez L, Pascual A, Jacoby G. Quinolone resistance from a transferable plasmid. The Lancet. London. 1998;351(9105): 797-9. (Pubitemid 28112342)
47. Mammeri H, Van De Loo M, Poirel L, Martínez-Martínez L, Nordmann P. Emergence of plasmid-mediated quinolone resistance in Escherichia coli in Europe. Antimicrob Agent Chemother. 2005;49(1):71-6. (Pubitemid 40065774)
48. Casellas JM. Contribuçao ao estudo de bactérias gram negativas do solo produtoras de ácidos ônicos, grupo lwoffi-glucidolitica. (Tesis magíster). Rio de Janeiro. Instituto de Microbiologia, Universidade Federal do Rio de Janeiro; 1968.
49. Hujer KM, Hamza NS, Hujer AM, Perez F, Helfand MS, Rice LB, et al. Identification of a new allelic variant of the Acinetobacter baumannii cephalosporinase, ADC-7 β-lactamase: defining a unique family of Class C enzymes. Antimicrob Agents Chemother. 2005;49(7): 2941-8. (Pubitemid 40917614)
50. Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis. 2006; 43(supl 2):S49-S56. (Pubitemid 44267140)
51. Quale J, Bratu S, Landman D, Heddurschetti R. Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii endemic in New York City. Clin Infect Dis. 2003;37(2):214-20. (Pubitemid 36930352)
52. Casellas JM, Tomé G, Farinati A, Borda N, Notario R, Méncez E, et al. Actividad de antibacterianos sobre Acinetobacter baumannii complex procedentes de pacientes con infecciones graves en Argentina. XV Congreso Panamericano de Infectología. Punta del Este, Uruguay. 2011. Abst SP2B-128. P. 10.
53. Limansky AS, Mussi MA, Viale AM. Loss of a 29-kilodalton outer membrane protein in Acinetobacter baumannii is associated with imipenem-resistance. J Clin Microbiol. 2002; 40(12):4776-8. (Pubitemid 35434989)
54. Casellas JM, Dana R. Is sulbactam really the answer for the treatment of infections caused by multiresistant strains of Acinetobacter spp? Enferm Infecc Microb Clin. 1996;14(9):524-7.
55. a encuesta del Comité de Resistencia a Antimicrobianos de la Asociación Panamericana de Infectología. Rev Panam Infectol. 2011;13(2):57-62.
56. Pachon-Ibáñez ME, Fernández-Cuenca F, Docobo-Pérez F, Pachón J, Pascual A. Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam. J. Antimicrob Chemother. 2006;58(3):689-92. (Pubitemid 44288142)
57. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008;21(23):538-82.
58. Rice LB. Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis. 2006;43(supl 2): S100-S5. (Pubitemid 44267148)
59. Acar JF. Problems and changing patterns of resistance with Gram-negative bacteria. Rev Infect Dis. 1985;7(Suppl 4):S545-S51.
60. Paterson DL, Hujer KM, Hujer AM, Yeiser B, Bonomo MD, Rice LB, et al. International Klebsiella Study Group. Antimicrob Agents Chemother. 2003;47(11):3554-60.
61. Aubert D, Poirel L, Chevalier J, Leotard S, Pages JM, Nordman P. Oxacillinase-mediated resistance to cefepime and susceptibility to ceftazidime in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2001;45(6):1615-20. (Pubitemid 32466325)